CoChat
Sign Up
Cited by 6Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic DiseasesDiabetes Management and Research

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effects of Incretin-based Therapy on High-sensitivity C-reactive Protein in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Open access
Wu, Yucheng, Lu, Yu, Yang, Shufang, Zhang, Qingqing·2021·Revista de Investigación Clínica
DOI 10.24875/ric.20000308
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Recently, studies had shown that incretin-based therapies could reduce the levels of pro-inflammatory markers. The data on the effects of incretin-based therapies on serum high-sensitivity C-reactive protein (hs-CRP) in type 2 diabetes (T2DM) were inconsistent. OBJECTIVE: The objective of the study was to assess the effects of incretin-based therapies on hs- CRP in patients with T2DM by meta-analysis. METHODS: We searched PubMed, EMBASE, the Cochrane Collaboration Library, and Web of Science to identify the eligible randomized clinical trials until August 2019. The pooled standard mean differences (SMD) were calculated by random-effects model using STATA 11.0. RESULTS: Twenty-five studies with 28 randomized controlled trials were finally included into the meta-analysis. Meta-analysis revealed a significant reduction in hs-CRP following treatment with incretin-based regimens compared to controls (SMD = -0.452, p < 0.001). Subgroup analysis of different class of incretinbased drugs showed that therapy with both dipeptidyl peptidase 4 inhibitors (DPP-4Is, SMD = -0.338, p = 0.026) and glucagonlike peptide 1 receptor agonists (GLP-1 RAs, SMD = -0.544, p = 0.003) caused significant reductions in hs-CRP. Besides, there was a significant reduction in hs-CRP with an intervention duration more than 24 weeks (SMD = -0.465, p = 0.001), while no significant difference with < 24 weeks. Meta-regression analyses showed that better glycemic control and more body mass index (BMI) decline were associated with hs-CRP reduction after incretin-based therapies. CONCLUSIONS: This meta-analysis suggests that incretin-based therapies, both GLP-1 RAs and DPP-4Is, can cause a significant reduction in hs-CRP in patients with T2DM, which is related to long intervention duration, better glycemic control, and more BMI decline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.24875/ric.20000308

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 40

  1. Jonas D, Van Scoyoc E, Gerrald K, Wines R, Amick H, Triplette M, et al. Drug Class Review: newer Diabetes Medications, TZDs, and Combinations: final Original Report. Portland, OR: CADTH; 2011.
  2. Drucker DJ, Nauck MA. The incretin system: glucagon-like pep- tide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet. 2006;368:1696-705.
  3. Ling J, Cheng P, Ge L, Zhang DH, Shi AC, Tian JH, et al. The ef- ficacy and safety of dipeptidyl peptidase-4 inhibitors for Type 2 diabetes: a bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol. 2019;56:249-72.
  4. Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-alpha and inflammatory cytokines and risk of Type 2 diabetes: a sys- tematic review and meta-analysis. Cytokine. 2016;86:100-9.
  5. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. JAMA. 2006;295:1681-7.
  6. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and dia- betic vascular complications. Diabetes Care. 1996;19:257-67.
  7. Tan KC, Wat NM, Tam SC, Janus ED, Lam TH, Lam KS. C-reactive protein predicts the deterioration of glycemia in chinese sub- jects with impaired glucose tolerance. Diabetes Care. 2003; 26:2323-8.
  8. Liu X, Men P, Wang B, Cai G, Zhao Z. Effect of dipeptidyl-pepti- dase-4 inhibitors on C-reactive protein in patients with Type 2 diabetes: a systematic review and meta-analysis. Lipids Health Dis. 2019;18:144.
  9. Strozik A, Steposz A, Basiak M, Drozdz M, Okopien B. Multifac- torial effects of vildagliptin added to ongoing metformin thera- py in patients with Type 2 diabetes mellitus. Pharmacol Rep. 2015;67:24-31.
  10. Takihata M, Nakamura A, Tajima K, Inazumi T, Komatsu Y, Tamura H, et al. Comparative study of sitagliptin with piogli- tazone in Japanese Type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013; 15:455-62.
  11. Shigiyama F, Kumashiro N, Miyagi M, Iga R, Kobayashi Y, Kanda E, et al. Linagliptin improves endothelial function in patients with Type 2 diabetes: a randomized study of linagliptin effectiveness on endothelial function. J Diabetes Investig. 2017;8:330-40.
  12. Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, et al. Sitagliptin attenuates the progression of carotid intima- media thickening in insulin-treated patients with Type 2 diabe- tes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016;39:455-64.
  13. Dei Cas A, Spigoni V, Cito M, Aldigeri R, Ridolfi V, Marchesi E, et al. Vildagliptin, but not glibenclamide, increases circulating en- dothelial progenitor cell number: a 12-month randomized con- trolled trial in patients with Type 2 diabetes. Cardiovasc Diabe- tol. 2017;16:27.
  14. Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with Type 2 diabe- tes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83.
  15. Park KS, Kwak S, Cho YM, Park KS, Jang HC, Kim SY, et al. Vilda- gliptin reduces plasma stromal cell-derived factor-1alpha in pa- tients with Type 2 diabetes compared with glimepiride. J Diabe- tes Investig. 2017;8:218-26.
  16. Kato H, Nagai Y, Ohta A, Tenjin A, Nakamura Y, Tsukiyama H, et al. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with Type 2 diabetes. Diabetes Res Clin Pract. 2015;109:199-205.
  17. Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with Type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110.
  18. Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL, et al. Left ventricular diastolic function in patients with Type 2 diabetes treated with a dipeptidyl peptidase-4 in- hibitor-a pilot study. Diabetol Metab Syndr. 2014;6:103.
  19. Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, et al. A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and meta- bolic parameters: sapporo athero-incretin study 1 (SAIS1). PLoS One. 2016;11:e0164255.
  20. Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaven- tura A, et al. Vildagliptin added to metformin on beta-cell func- tion after a euglycemic hyperinsulinemic and hyperglycemic clamp in Type 2 diabetes patients. Diabetes Technol Ther. 2012;14:475-84.
  21. Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, beta-cell function and insulin resistance in Type 2 diabetic patients. Diabetes Res Clin Pract. 2012;98:51-60.
  22. Koren S, Shemesh-Bar L, Tirosh A, Peleg RK, Berman S, Hamad RA, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in Type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012; 14:561-7.
  23. Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nak- agawachi R, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in Type 2 diabetic patients. Metabolism. 2013;62:347-51.
  24. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, et al. Exenatide plus metformin compared with metformin alone on beta-cell function in patients with Type 2 diabetes. Diabet Med. 2012;29:1515-23.
  25. Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and Type 2 diabetes: a prospective randomized clinical trial using magnetic reso- nance imaging and spectroscopy. Diabetes Obes Metab. 2016; 18:882-91.
  26. Wu JD, Xu XH, Zhu J, Ding B, Du TX, Gao G, et al. Effect of exenatide on inflammatory and oxidative stress markers in pa- tients with Type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:143-8.
  27. Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A, et al. A comparison of the effects of the GLP-1 analogue li- raglutide and insulin glargine on endothelial function and meta- bolic parameters: a randomized, controlled trial sapporo athero- incretin study 2 (SAIS2). PLoS One. 2015;10:e0135854.
  28. Faurschou A, Gyldenlove M, Rohde U, Thyssen JP, Zachariae C, Skov L, et al. Lack of effect of the glucagon-like peptide-1 recep- tor agonist liraglutide on psoriasis in glucose-tolerant patients- -a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29:555-9.
  29. Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Suny- er FX, et al. Effects of taspoglutide on glycemic control and body weight in obese patients with Type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring). 2013;21:238-47.
  30. Pratley RE, Urosevic D, Boldrin M, Balena R, Group TE. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with Type 2 diabetes uncontrolled with sulphonylurea or sulpho- nylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). Diabetes Obes Metab. 2013;15:234-40.
  31. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs gliben- clamide monotherapy in Japanese patients with Type 2 diabe- tes. Curr Med Res Opin. 2010;26:1013-22.
  32. Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglu- tide as add-on to sulphonylurea in Japanese patients with Type 2 diabetes. Diabetes Obes Metab. 2010;12:341-7.
  33. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010;12:233-40.
  34. Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB, et al. The effect of liraglutide on endothelial function in patients with Type 2 diabetes. Diab Vasc Dis Res. 2014;11:419-30.
  35. Beck-Nielsen H. Glucagon-like peptide 1 analogues in the treatment of Type 2 diabetes mellitus. Ugeskr Laeger. 2012;174:1606-8.
  36. Dhindsa S, Tripathy D, Mohanty P, Ghanim H, Syed T, Aljada A, et al. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kap- paB in mononuclear cells. Metabolism. 2004;53:330-4.
  37. Guo C, Huang T, Chen A, Chen X, Wang L, Shen F, et al. Glucagon- like peptide 1 improves insulin resistance in vitro through anti- inflammation of macrophages. Braz J Med Biol Res. 2016;49:e5826.
  38. Xian Y, Chen Z, Deng H, Cai M, Liang H, Xu W, et al. Exenatide mitigates inflammation and hypoxia along with improved angio- genesis in obese fat tissue. J Endocrinol. 2019;242:79-89.
  39. Zhuge F, Ni Y, Nagashimada M, Nagata N, Xu L, Mukaida N, et al. DPP-4 inhibition by linagliptin attenuates obesity-related in- flammation and insulin resistance by regulating M1/M2 macro- phage polarization. Diabetes. 2016;65:2966-79.
  40. Mozafari N, Azadi S, Mehdi-Alamdarlou S, Ashrafi H, Azadi A. Inflammation: a bridge between diabetes and COVID-19, and possible management with sitagliptin. Med Hypotheses. 2020; 143:110-1.

Cited by

Sorted by citations

Metadata

Authors
Wu, Y., Lu, Y., Yang, S., & Zhang, Q.
Affiliations
The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
ORCID
Venue
Revista de Investigación Clínica
Publisher
Elsevier BV
Published
2021-03
Volume
73
Issue
2
Pages
100-110
ISSN
0034-8376 (ISSN-L)
DOI
10.24875/ric.20000308
OpenAlex
W3094103974
Cited by
6
References
5
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1
FWCI
0.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Revista de investigaci�n Cl�nica (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Nantong University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
incretin-based therapy, high-sensitivity C-reactive protein, type 2 diabetes, DPP-4 inhibitors, GLP-1 receptor agonists, inflammation, glycemic control, treatment duration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review